Research-Studien

Seite 2 von 310

24.11.21  DGAP-Research-Studien: Diversified Energy PLC
(von First Berlin Equity Research GmbH): Kaufen Diversified Energy PLC
24.11.21  DGAP-Research-Studien: Netfonds AG
(von Montega AG): Kaufen
22.11.21  DGAP-Research-Studien: IGEA Pharma N.V.
(von GBC AG): BUY
22.11.21  DGAP-Research-Studien: EQS Group AG
(von GBC AG): Kaufen
22.11.21  DGAP-Research-Studien: German Real Estate Capital S.A.
(von GBC AG): Stark überdurchschnittlich attraktiv German Real Est [...]
22.11.21  DGAP-Research-Studien: USU Software AG
(von GBC AG): Kaufen
22.11.21  DGAP-Research-Studien: ad pepper media International N.V.
(von First Berlin Equity Research GmbH): Buy
22.11.21  DGAP-Research-Studien: Aspermont Limited
(von GBC AG): Kaufen Aspermont Limited
22.11.21  DGAP-Research-Studien: Aspermont Limited
(von GBC AG): BUY Aspermont Limited
19.11.21  DGAP-Research-Studien: Li-Metal Corp.
(von Sphene Capital GmbH): Buy
19.11.21  DGAP-Research-Studien: ERWE Immobilien AG
(von GSC Research GmbH): Kaufen
19.11.21  DGAP-Research-Studien: 2G Energy AG
(von First Berlin Equity Research GmbH): Hinzufügen
18.11.21  DGAP-Research-Studien: Media and Games Invest SE
(von First Berlin Equity Research GmbH): Buy
18.11.21  DGAP-Research-Studien: All for One Group SE
(von BankM AG): Kaufen
17.11.21  DGAP-Research-Studien: GBC Insider Focus Index
(von GBC AG): GBC Insider Focus Index
17.11.21  DGAP-Research-Studien: West Mining Corp.
(von Sphene Capital GmbH): Buy West Mining Corp.
17.11.21  DGAP-Research-Studien: Energiekontor AG
(von First Berlin Equity Research GmbH): Hinzufügen
16.11.21  DGAP-Research-Studien: windeln.de SE
(von Montega AG): n.a.
16.11.21  DGAP-Research-Studien: SFC Energy AG
(von First Berlin Equity Research GmbH): Buy
16.11.21  DGAP-Research-Studien: Cardiol Therapeutics Inc.
(von GBC AG): Kaufen

Indizes

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021